Candel Therapeutics Financial Ratios
NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
9.94+0.28 (+2.90%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Candel Therapeutics ratio analysis
Return on equity reached -73.5%, meaning Candel Therapeutics generated -0.74 dollars of profit for every dollar of shareholders' equity. Debt-to-equity stood at 0.02 versus 0.18 the year before, and the current ratio was 13.49. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Candel Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | — | — | — | 412.75 | 1,180.70 | — |
| Price / book | 5.55 | 4.40 | 3.34 | 1.08 | 2.30 | — |
| Operating margin | — | — | — | -27,777.6% | -20,580.8% | -11,048.0% |
| Net margin | — | — | — | -15,035.2% | -28,899.2% | -14,144.0% |
| Free cash flow margin | — | — | — | -26,172.8% | -19,242.4% | -8,437.6% |
| Return on equity (ROE) | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% | — |
| Return on assets (ROA) | -30.5% | -51.6% | -92.1% | -24.2% | -40.5% | -46.2% |
| Debt / equity | 0.02 | 0.18 | 1.61 | 0.01 | 0.01 | — |
| Current ratio | 13.49 | 2.77 | 2.59 | 12.81 | 15.84 | 7.46 |
| Revenue growth | — | — | — | 0.0% | 0.0% | — |